Search

Your search keyword '"von Tresckow, Bastian"' showing total 248 results
Start Over Author "von Tresckow, Bastian" Publication Year Range Last 50 years Journal blood
248 results on '"von Tresckow, Bastian"'

1. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Author

Dreyling, Martin, Fowler, Nathan Hale, Dickinson, Michael, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, José Antonio, Chen, Andy I., Nastoupil, Loretta J., von Tresckow, Bastian, María Ferreri, Andrés José, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Paule, Ines, Zia, Aiesha, Awasthi, Rakesh, Han, Xia, Germano, Davide, O’Donovan, Darragh, Ramos, Roberto, Maier, Harald J., Masood, Aisha, Thieblemont, Catherine, and Schuster, Stephen J.

Published
2024
Full Text
View/download PDF

2. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Author

Heger, Jan-Michel, Mattlener, Julia, Schneider, Jessica, Gödel, Philipp, Sieg, Noëlle, Ullrich, Fabian, Lewis, Richard, Bucaciuc-Mracica, Teodora, Schwarz, Roland F., Rueß, Daniel, Ruge, Maximilian I., Montesinos-Rongen, Manuel, Deckert, Martina, Blau, Tobias, Kutsch, Nadine, Balke-Want, Hyatt, Weiss, Jonathan, Becker, Kerstin, Reinhardt, H. Christian, Hallek, Michael, Borchmann, Peter, von Tresckow, Bastian, and Borchmann, Sven

Published
2024
Full Text
View/download PDF

3. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Author

Armand, Philippe, Zinzani, Pier Luigi, Lee, Hun Ju, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Herrera, Alex F., Lin, Jianxin, Kim, Eunhee, Chakraborty, Samhita, Marinello, Patricia, and Moskowitz, Craig H.

Published
2023
Full Text
View/download PDF

5. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Author

Bethge, Wolfgang A., Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Marie, Wulf, Gerald G., Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Fante, Matthias A., Schroers, Roland, Bayir, Lale, Borchmann, Peter, Buecklein, Veit, Hasenkamp, Justin, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

6. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Author

Reinke, Sarah, Bröckelmann, Paul J., Iaccarino, Ingram, Garcia-Marquez, Maria, Borchmann, Sven, Jochims, Franziska, Kotrova, Michaela, Pal, Karol, Brüggemann, Monika, Hartmann, Elena, Sasse, Stephanie, Kobe, Carsten, Mathas, Stephan, Soekler, Martin, Keller, Ulrich, Bormann, Matthias, Zimmermann, Andreas, Richter, Julia, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Schlößer, Hans, von Bergwelt-Baildon, Michael, Rosenwald, Andreas, Engert, Andreas, and Klapper, Wolfram

Published
2020
Full Text
View/download PDF

9. Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Bühnen, Ina, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Herhaus, Peter, additional, Halbsguth, Teresa V, additional, Schaub, Valdete, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Bormann, Matthias, additional, Dickhut, Andreas, additional, Kaul, Helen, additional, Fuchs, Michael, additional, Kobe, Carsten, additional, Baues, Christian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2022
Full Text
View/download PDF

11. Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Author

Heger, Jan-Michel, primary, Mattlener, Julia, additional, Gödel, Philipp, additional, Balke-Want, Hyatt, additional, Sieg, Noëlle, additional, Kutsch, Nadine, additional, Becker, Kerstin, additional, Weiss, Jonathan, additional, Reinhardt, H. Christian, additional, Hallek, Michael, additional, Borchmann, Peter, additional, von Tresckow, Bastian, additional, and Borchmann, Sven, additional

Published
2022
Full Text
View/download PDF

12. Novel Autochthonous Mouse Models of Serve As Preclinical Tools to Investigate Pathogenesis and Treatment of MCD/C5 DLBCL

Author

Flümann, Ruth, primary, Hansen, Julia, additional, Pelzer, Benedikt, additional, Kisis, Ilmars, additional, Lohmann, Tim, additional, Persigehl, Thorsten, additional, Abedpour, Nima, additional, Peifer, Martin, additional, Buettner, Reinhard, additional, von Tresckow, Bastian, additional, Jachimowicz, Ron, additional, Reinhardt, Hans Christian, additional, and Knittel, Gero, additional

Published
2022
Full Text
View/download PDF

13. Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Author

Dreyling, Martin, primary, Dickinson, Michael, additional, Martinez Lopez, Joaquin, additional, Kolstad, Arne, additional, Butler, Jason P, additional, Ghosh, Monalisa, additional, Popplewell, Leslie L., additional, Chavez, Julio, additional, Bachy, Emmanuel, additional, Kato, Koji, additional, Harigae, Hideo, additional, Kersten, Marie Jose, additional, Andreadis, Charalambos, additional, Riedell, Peter A., additional, Ho, Phoebe Joy, additional, Perez-Simon, Jose A., additional, Chen, Andy, additional, Nastoupil, Loretta J., additional, von Tresckow, Bastian, additional, Ferreri, Andrés J M, additional, Teshima, Takanori, additional, Patten, Piers E.M., additional, McGuirk, Joseph P., additional, Petzer, Andreas, additional, Offner, Fritz, additional, Viardot, Andreas, additional, Zinzani, Pier Luigi, additional, Malladi, Ram, additional, Paule, Ines, additional, Zia, Aiesha, additional, Awasthi, Rakesh, additional, Han, Xia, additional, Germano, Davide, additional, O'Donovan, Darragh, additional, Ramos, Roberto, additional, Masood, Aisha, additional, Thieblemont, Catherine, additional, Fowler, Nathan H., additional, and Schuster, Stephen J., additional

Published
2022
Full Text
View/download PDF

15. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann-Grill, Karolin, additional, Kobbe, Guido, additional, Wilhelm, Martin, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William Hermann, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch-Ulrich, Kathleen, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J, additional

Published
2021
Full Text
View/download PDF

16. A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma

Author

Flümann, Ruth, primary, Nieper, Pascal, additional, Lohmann, Tim, additional, Kisis, Ilmars, additional, Peifer, Martin, additional, Abedpour, Nima, additional, Thomas, Roman, additional, Kochanek, Moritz, additional, Pelzer, Benedikt, additional, Beleggia, Filippo, additional, Buettner, Reinhard, additional, Lohneis, Philipp, additional, Persigehl, Thorsten, additional, Hallek, Michael, additional, Calado, Dinis Pedro, additional, Pasqualucci, Laura, additional, von Tresckow, Bastian, additional, Chapuy, Björn, additional, Jachimowicz, Ron, additional, Reinhardt, Christian, additional, and Knittel, Gero, additional

Published
2021
Full Text
View/download PDF

17. Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Author

Thieblemont, Catherine, primary, Dickinson, Michael, additional, Martinez-Lopez, Joaquin, additional, Kolstad, Arne, additional, Butler, Jason P, additional, Ghosh, Monalisa, additional, Popplewell, Leslie L., additional, Chavez, Julio C., additional, Bachy, Emmanuel, additional, Kato, Koji, additional, Harigae, Hideo, additional, Kersten, Marie Jose, additional, Andreadis, Charalambos, additional, Riedell, Peter A., additional, Ho, P. Joy, additional, Pérez-Simón, Jose, additional, Chen, Andy, additional, Nastoupil, Loretta, additional, Von Tresckow, Bastian, additional, Ferreri, Andres JM, additional, Teshima, Takanori, additional, Patten, Piers EM, additional, McGuirk, Joseph P., additional, Petzer, Andreas, additional, Offner, Fritz, additional, Viardot, Andreas, additional, Zinzani, Pier Luigi, additional, Malladi, Ram, additional, Zia, Aiesha, additional, Lobetti Bodoni, C, additional, Masood, Aisha, additional, Schuster, Stephen J., additional, Fowler, Nathan H., additional, and Dreyling, Martin H., additional

Published
2021
Full Text
View/download PDF

19. Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Author

Heger, Jan-Michel, primary, Graef, Claus Moritz, additional, Falderbaum, Philipp, additional, Gödel, Philipp, additional, Balke-Want, Hyatt, additional, Simon, Florian, additional, Sieg, Noëlle, additional, Naendrup, Jan-Hendrik, additional, Neumann, Marie Anne-Catherine, additional, Gillessen, Sarah, additional, Bröckelmann, Paul J, additional, Eichenauer, Dennis A., additional, Borchmann, Peter, additional, and Von Tresckow, Bastian, additional

Published
2021
Full Text
View/download PDF

20. Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Author

Armand, Philippe, primary, Kuruvilla, John, additional, Herrera, Alex F., additional, Ribrag, Vincent, additional, Brice, Pauline, additional, Thieblemont, Catherine, additional, Von Tresckow, Bastian, additional, Kim, Eunhee, additional, Orlowski, Robert, additional, Chakraborty, Samhita, additional, Marinello, Patricia, additional, and Zinzani, Pier Luigi Luigi, additional

Published
2021
Full Text
View/download PDF

21. Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma

Author

Salles, Gilles, primary, Schuster, Stephen J., additional, Dreyling, Martin H., additional, Fischer, Luca, additional, Kuruvilla, John, additional, Patten, Piers EM, additional, Von Tresckow, Bastian, additional, Smith, Sonali M., additional, Jiminez Ubieto, Ana Isabel, additional, Davis, Keith L., additional, Anjos, Carla, additional, Chu, Jufen, additional, Zhang, Jie, additional, Lobetti Bodoni, C, additional, Thieblemont, Catherine, additional, Fowler, Nathan H., additional, Dickinson, Michael, additional, Martinez-Lopez, Joaquin, additional, Wang, Yucai, additional, and Link, Brian K., additional

Published
2021
Full Text
View/download PDF

22. Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Author

Armand, Philippe, primary, Zinzani, Pier Luigi Luigi, additional, Lee, Hun Ju, additional, Johnson, Nathalie, additional, Brice, Pauline, additional, Radford, John, additional, Ribrag, Vincent, additional, Molin, Daniel, additional, Vassilakopoulos, Theodoros P., additional, Tomita, Akihiro, additional, von Tresckow, Bastian, additional, Shipp, Margaret A., additional, Herrera, Alex F., additional, Lin, Jianxin, additional, Kim, Eunhee, additional, Chakraborty, Samhita, additional, Marinello, Patricia, additional, and Moskowitz, Craig H., additional

Published
2021
Full Text
View/download PDF

23. A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL)

Author

Salles, Gilles, primary, Schuster, Stephen J., additional, Fischer, Luca, additional, Kuruvilla, John, additional, Patten, Piers EM, additional, von Tresckow, Bastian, additional, Smith, Sonali M., additional, Jiminez Ubieto, Ana Isabel, additional, Davis, Keith L., additional, Nagar, Saurabh P, additional, Zhang, Jie, additional, Bollu, Vamsi, additional, Jousseaume, Etienne, additional, Ramos, Roberto, additional, Wang, Yucai, additional, and Link, Brian K., additional

Published
2021
Full Text
View/download PDF

24. Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Author

Bethge, Wolfgang A, primary, Martus, Peter, additional, Schmitt, Michael, additional, Holtick, Udo, additional, Borchmann, Peter, additional, Subklewe, Marion, additional, Rejeski, Kai, additional, von Tresckow, Bastian, additional, Ayuk, Francis A., additional, Kroeger, Nicolaus, additional, Wagner-Drouet, Eva-Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Lengerke, Claudia, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

25. Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Author

Hess, Georg, Vucinic, Vladan, Rejeski, Kai, Aydilek, Enver, Simon, Linda, Penack, Olaf, Koenecke, Christian, von Bonin, Malte, von Tresckow, Bastian, Fehr, Martin, Pott, Christiane, Stilgenbauer, Stephan, Leng, Corinna, Schroers, Roland, Duell, Johannes, Marks, Reinhard, Mueller, Fabian, Brunnberg, Uta, Kerkhoff, Andrea, Ohler, Anke, Wagner Drouet, Eva-Maria, Schmidtmann, Irene, Theobald, Matthias, Dreyling, Martin, and Dreger, Peter

Published
2023
Full Text
View/download PDF

26. Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Author

Fowler, Nathan H, Dickinson, Michael, Dreyling, Martin, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason P, Ghosh, Monalisa, Popplewell, Leslie L., Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, Jose Antonio, Nagle, Sarah J., Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andres JM, Teshima, Takanori, Patten, Piers, McGuirk, Joseph P., Petzer, Andreas, Offner, Fritz C., Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Bubuteishvili Pacaud, Lida, Forcina, Alessandra, Zia, Aiesha, Schuster, Stephen J., and Thieblemont, Catherine

Published
2020
Full Text
View/download PDF

27. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Author

Udo Holtick, Claudia Lengerke, Peter Borchmann, Kai Rejeski, Reinhard Marks, Claudia D. Baldus, Malte von Bonin, Bertram Glass, Francis Ayuk, Wolfgang Bethge, Christian Koenecke, Marion Subklewe, Simone Thomas, Gerald Wulf, Roland Schroers, von Tresckow Bastian, Olaf Penack, Daniel Wolff, Eva Wagner, Vladan Vucinic, Nicolaus Kröger, Dietrich W. Beelen, Maria-Luisa Schubert, Peter Dreger, Matthias Stelljes, Max S. Topp, Ulf Schnetzke, Dimitrios Mougiakakos, and Christine Hanoun

Subjects
Oncology, medicine.medical_specialty, Standard of care, business.industry, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Internal medicine, Medicine, CAR T-cell therapy, Nonrelapse mortality, business, B-cell lymphoma
Abstract

Introduction Although the labeled CD19 targeting CAR-T cell constructs axi-cel and tisa-cel are generally associated with an acceptable safety profile, non-relapse deaths can occur. Little is known about timing, causes and predictors of NRM following SOC CAR-T cell therapy for LBCL. Here, we analyzed frequency, causes, and risk factors of non-relapse deaths with focus on late NRM (beyond 4 weeks after dosing) using registry data provided by the DRST, the national partner of the EBMT. Methods Patients were selected from 356 consecutive patients who received SOC CAR-T treatment of LBCL between November 2018 and April 2021 at 21 German centers and were registered with the DRST/EBMT. Baseline patient, disease, and transplant data were collected from MED-A cellular therapy forms. Centers were contacted to provide additional treatment and follow-up information. Patients with late NRM (defined as NRM occurring beyond 4 weeks after dosing without prior LBCL relapse or progression) were compared with all patients surviving progression-free the 4-week landmark after dosing without subsequent NRM. Cumulative incidences of NRM were calculated considering relapse/progression as competing event. Results The analysis set consisted of 312 patients surviving progression-free at least 28 days after CAR-T treatment and remained alive until the end of follow-up or had a documented cause of death. Median age was 61 years (19-83), 66% were male, 52% had an IPI ≥3, 13 had an ECOG score >1, 70% had received ≥3 treatment lines, 33% had failed a prior HCT, and 78% were refractory at lymphodepletion. 50% had been treated at a center contributing ≥20 cases with axi-cel (52%) or tisa-cel (48%). Grade ≥3 CRS and grade ≥3 neurotoxicity (NT) had occurred in 11% each, and 7% had no neutrophil recovery at day 100 post dosing or at last follow-up, whatever was earlier. With a median follow-up of 11.2 months, 124 patients (40%) had died, 109 (35%) LBCL-related, and 15 (5%) because of NRM. The cumulative incidence of late NRM at 12 months post dosing was 4.3% (95%CI 2.0-6.6). Causes of NRM were infections in 10 patients (bacterial or fungal sepsis/pneumonia 6; viral/atypical pneumonia/encephalitis 4); late NT 2; hyperinflammatory syndrome 1; 2 nd malignancy 1; unknown 1). Of note, 5 of the 6 lethal fungal/bacterial infections occurred subsequent to high grade NT. There was no significant difference between patients experiencing and not experiencing NRM in terms of age, gender, IPI, ECOG, pretreatment lines, prior HCT, disease status at lymphodepletion, and grade ≥3 CRS frequency. However, a significantly larger proportion of patients with late NRM had failed neutrophil recovery (27% vs 5%, p 0.011), had experienced grade ≥3 NT (40% vs 10%, p 0.0031), and/or had received axi-cel (93% vs 51%, p 0.001). Patients having neutrophil non-recovery and/or grade ≥3 NT had a 12-month NRM incidence of 16% (95%CI 5.1-26.9) vs 2.5% (95%CI 0.3-4.7) in patients with none of these 2 factors. Conclusions Late NRM in patients receiving SOC CAR-T treatment for LBCL is largely driven by infections. Risk factors for late NRM appear to be protracted neutropenia and higher grade NT, suggesting that intensified anti-bacterial/anti-fungal prophylaxis may be considered in patients with persisting critical neutropenia or exposed to high-dose steroids for NT treatment. Figure 1 Figure 1. Disclosures Dreger: BMS: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Bluebird Bio: Consultancy; AbbVie: Consultancy, Speakers Bureau; Gilead Sciences: Consultancy, Speakers Bureau; Janssen: Consultancy; Novartis: Consultancy, Speakers Bureau; Riemser: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau. Schubert: Gilead: Consultancy. Holtick: Sanofi: Honoraria; Celgene: Honoraria. Subklewe: Miltenyi: Research Funding; Takeda: Speakers Bureau; Gilead: Consultancy, Research Funding, Speakers Bureau; Klinikum der Universität München: Current Employment; MorphoSys: Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Roche: Research Funding; Seattle Genetics: Consultancy, Research Funding; Pfizer: Consultancy, Speakers Bureau; Janssen: Consultancy; BMS/Celgene: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau. Bastian: Abbvie: Other; Amgen: Consultancy, Honoraria; Astra Zeneca: Honoraria, Other; BMS and Celgene: Consultancy, Honoraria, Other; Kite-Gilead: Consultancy, Honoraria; MSD: Consultancy, Honoraria, Other, Research Funding; Novartis: Consultancy, Honoraria, Other, Research Funding; Pentixafarm: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other, Research Funding. Ayuk: Gilead: Honoraria; Celgene/BMS: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Miltenyi Biomedicine: Honoraria; Mallinckrodt/Therakos: Honoraria, Research Funding; Novartis: Honoraria. Marks: Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Honoraria; Merck: Consultancy; AbbVie: Other: Meeting attendance. Penack: Priothera: Consultancy; Takeda: Research Funding; Incyte: Research Funding; Neovii: Honoraria; Pfizer: Honoraria; Therakos: Honoraria; Novartis: Honoraria; MSD: Honoraria; Jazz: Honoraria; Gilead: Honoraria; Astellas: Honoraria; Shionogi: Consultancy; Omeros: Consultancy. Koenecke: EUSA Pharm: Consultancy; Kite/Gilead: Consultancy; BMS/Celgene: Consultancy; Janssen: Consultancy; Novartis: Consultancy. Von Bonin: Daiichi Sankyo: Other: traveling support and advisory fees; Novartis: Other: traveling support and advisory fees; Kite/Gilead: Other: traveling support and advisory fees. Stelljes: Novartis: Consultancy, Speakers Bureau; MSD: Consultancy, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Medac: Speakers Bureau; Celgene/BMS: Consultancy, Speakers Bureau; Kite/Gilead: Consultancy, Speakers Bureau. Glass: BMS: Consultancy; Helios Klinik Berlin-Buch: Current Employment; Kite: Consultancy; Novartis: Consultancy; Riemser: Research Funding; Roche: Consultancy, Research Funding, Speakers Bureau. Baldus: Novartis: Honoraria; Amgen: Honoraria; Celgene/BMS: Honoraria; Jazz: Honoraria. Vucinic: MSD: Honoraria; Novartis: Honoraria; Gilead: Honoraria, Other: Travel Sponsoring; Janssen: Honoraria, Other: Travel Sponsoring; Abbvie: Honoraria, Other: Travel Sponsoring. Topp: Universitatklinikum Wurzburg: Current Employment; Celgene: Consultancy, Research Funding; Janssen: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Novartis: Consultancy; Roche: Consultancy, Research Funding; Gilead: Research Funding; Regeneron: Consultancy, Research Funding; Macrogeniecs: Research Funding; Amgen: Consultancy, Research Funding. Schroers: BMS/Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Takeda: Honoraria. Hanoun: AstraZeneca: Honoraria; Abbvie: Other: travel expenses; Novartis: Research Funding. Thomas: AbbVie: Honoraria, Speakers Bureau; Art tempi: Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Other, Research Funding, Speakers Bureau; EUSA Pharma: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other; Kite/Gilead: Honoraria, Other, Research Funding, Speakers Bureau; Medigene: Consultancy, Honoraria, Other; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other; Pfizer: Consultancy, Honoraria, Other, Speakers Bureau. Kröger: Novartis: Research Funding; Riemser: Honoraria, Research Funding; Sanofi: Honoraria; Neovii: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Gilead/Kite: Honoraria; Celgene: Honoraria, Research Funding; AOP Pharma: Honoraria. Bethge: Novartis: Consultancy, Honoraria, Speakers Bureau; Miltenyi Biotec: Consultancy, Honoraria, Research Funding, Speakers Bureau; Kite-Gilead: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau.

Published
2021

28. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann, Karolin, additional, Halbsguth, Teresa V, additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

29. AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Author

Sasse, Stephanie, primary, Momotow, Jesko, additional, Plütschow, Annette, additional, Hüttmann, Andreas, additional, Basara, Nadezda, additional, Koenecke, Christian, additional, Martin, Sonja, additional, Bentz, Martin, additional, Grosse-Thie, Christina, additional, Thorspecken, Sven, additional, de Wit, Maike, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

30. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Author

Bröckelmann, Paul J, primary, Goergen, Helen, primary, Keller, Ulrich, primary, Meissner, Julia, primary, Ordemann, Rainer, primary, Halbsguth, Teresa V, primary, Sasse, Stephanie, primary, Sökler, Martin, primary, Kerkhoff, Andrea, primary, Mathas, Stephan, primary, Hüttmann, Andreas, primary, Bormann, Matthias, primary, Zimmermann, Andreas, primary, Fuchs, Michael, primary, von Tresckow, Bastian, primary, Baues, Christian, primary, Rosenwald, Andreas, primary, Klapper, Wolfram, primary, Kobe, Carsten, primary, Borchmann, Peter, primary, and Engert, Andreas, primary

Published
2019
Full Text
View/download PDF

31. Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Author

Zinzani, Pier Luigi, primary, Lee, Hun Ju, primary, Armand, Philippe, primary, Johnson, Nathalie, primary, Brice, Pauline, primary, Radford, John, primary, Ribrag, Vincent, primary, Molin, Daniel, primary, Vassilakopoulos, Theodoros P., primary, Tomita, Akihiro, primary, Von Tresckow, Bastian, primary, Shipp, Margaret A., primary, Herrera, Alex F., primary, Lin, Jianxin, primary, Kim, Eunhee, primary, Farooqui, Mohammed, primary, Marinello, Patricia, primary, and Moskowitz, Craig H., primary

Published
2019
Full Text
View/download PDF

32. Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Author

Gillessen, Sarah, primary, Plütschow, Annette, primary, Fuchs, Michael, primary, Markova, Jana, primary, Greil, Richard, primary, Topp, Max S., primary, Meissner, Julia, primary, Zijlstra, Josée M, primary, Eichenauer, Dennis A., primary, Diehl, Volker, primary, Borchmann, Peter, primary, Engert, Andreas, primary, and von Tresckow, Bastian, primary

Published
2019
Full Text
View/download PDF

33. Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Author

von Tresckow, Bastian, primary, Hüttmann, Andreas, additional, Vucinic, Vladan, additional, Mueller, Horst, additional, Plütschow, Annette, additional, Viardot, Andreas, additional, Topp, Max S., additional, Kobe, Carsten, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Haverkamp, Heinz, additional, Fuchs, Michael, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2018
Full Text
View/download PDF

34. Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Author

Zinzani, Pier Luigi, primary, Chen, Robert W., additional, Lee, Hun Ju, additional, Armand, Philippe, additional, Johnson, Nathalie A, additional, Brice, Pauline, additional, Radford, John, additional, Ribrag, Vincent, additional, Molin, Daniel, additional, Vassilakopoulos, Theodoros P., additional, Tomita, Akihiro, additional, Von Tresckow, Bastian, additional, Shipp, Margaret A., additional, Kim, Eunhee, additional, Nahar, Akash, additional, Balakumaran, Arun, additional, and Moskowitz, Craig H., additional

Published
2018
Full Text
View/download PDF

35. PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Author

Fuchs, Michael, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Eich, Hans, additional, Baues, Christian, additional, Greil, Richard, additional, Sasse, Stephanie, additional, Zijlstra, Josée M, additional, Lohri, Andreas, additional, Rosenwald, Andreas, additional, von Tresckow, Bastian, additional, Diehl, Volker, additional, Kuhnert, Georg, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2018
Full Text
View/download PDF

36. Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Author

Bröckelmann, Paul J, Müller, Horst, Gillessen, Sarah, Jacob, Anne Sophie, Momotow, Jesko, Damaschin, Carla, Ferdinandus, Justin, Yang, Xiaoqin, Fuchs, Michael, Kobe, Carsten, Eich, Hans Theodor, Engert, Andreas, Borchmann, Peter, and von Tresckow, Bastian

Abstract

Background: Progression-free survival (PFS) and overall survival (OS) are predominant measures of treatment efficacy in Hodgkin lymphoma (HL). Despite preference for OS from many regulatory authorities, PFS is most relevant to patients and frequently serves as primary endpoint in clinical trials. Recently we found a strong correlation between treatment effects on PFS and OS in the first-line setting (Bröckelmann PJ et al. EHA23/ICML23). However, their relationship in the relapsed setting remains unclear. We aimed to evaluate the correlation of PFS with OS after treatment of relapsed HL.

Published
2023
Full Text
View/download PDF

37. Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

Author

von Tresckow, Bastian, Costa, Pau Abrisqueta, Aggarwal, Shivani, Hampp, Christian, Walsh, Laura, Thorley, Eileen, Shah, Mohsin, Ma, Qiufei, and Jimenez Ubieto, Ana

Abstract

Introduction:A multi-center multi-country retrospective cohort study (ORCHID [NCT05338879]), using real-world data (RWD) from electronic medical records (EMRs) and research databases, for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) treated with standard of care is being conducted to contextualize treatment outcomes in a single-arm trial. A systematic literature review (SLR) was carried out to identify baseline prognostic factors that will be evaluated for imbalances between cohorts in the single-arm trial and RWD study. This SLR was followed by an evidence-based clinical expert review of prognostic variables and ranking in order of importance for the ORCHID study as described herein.

Published
2023
Full Text
View/download PDF

38. Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Author

Bröckelmann, Paul J, Bühnen, Ina, Herhaus, Peter, Meissner, Julia, Trautmann-Grill, Karolin, Müller, Horst, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas, and Behringer, Karolin

Abstract

Background: First-line treatment of patients with classical Hodgkin lymphoma (HL) with anti-PD1 antibodies in combination with AVD chemotherapy is highly effective across risk-groups. Based on encouraging phase II and ongoing phase III trials, anti-PD1 based first-line treatment may hence soon become a first-line treatment option. To date, no data on fertility and gonadal function after anti-PD1 based first-line HL treatment is available. Herein, we present data on pregnancies and gonadal function in patients treated within the randomized GHSG phase II NIVAHL trial.

Published
2023
Full Text
View/download PDF

39. Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Author

Ossami Saidy, Anna, Fuhrmann, Stephan, Peczynski, Christophe, Boumendil, Ariane, Michel, Eva, Galimard, Jacques-Emmanuel, Finel, Hervé, Daskalakis, Michael, Novak, Urban, Beauvais, David, Vandenberghe, Peter, Kröger, Nicolaus, Ram, Ron, Finke, Jürgen, Stelljes, Matthias, Wulf, Gerald G., Bethge, Wolfgang Andreas, von Bonin, Malte, Bug, Gesine, Kuhnl, Andrea, Passweg, Jakob, Stoelzel, Friedrich, von Tresckow, Bastian, Sureda Balari, Anna Maria, Dreger, Peter, Schmitz, Norbert, and Glass, Bertram

Abstract

Introduction: The prognosis of patients (pts) with relapsed or refractory (r/r) large B cell lymphoma (LBCL) and central nervous system (CNS) involvement is dismal. Standard treatment for pts with r/r LBCL are anti-CD19 chimeric antigen receptor T-cells (CART). Several reports with limited numbers of patients suggest that CART might also be an effective treatment for pts with CNS lymphoma. This EBMT registry study aimed at compiling data to investigate the potential of CART in pts with primary (PCNSL) or secondary CNS lymphoma (SCNCL).

Published
2023
Full Text
View/download PDF

40. An In VivoPiggyBacInsertional Mutagenesis Screen Reveals Oncogenic Lesions Cooperating with Myd88 L265P

Author

Höfmann, Svenja, Flümann, Ruth, Hansen, Julia, Klein, Sebastian, Meinel, Jörn, Pfeiffer, Pauline, Goldfarb-Wittkopf, Hannah, Lütz, Anna, Wirtz, Jessica, Möllmann, Michael, Zhou, Tanja, Tabatabai, Areya, Lohmann, Tim, Beleggia, Filippo, Pelzer, Benedikt, Ullrich, Fabian, Arora, Aastha, Persigehl, Thorsten, Büttner, Reinhard, von Tresckow, Bastian, Jachimowicz, Ron, Knittel, Gero, and Reinhardt, Hans Christian

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common Non-Hodgkin lymphoma and originates from transformed germinal center-experienced B cells. Traditionally, DLBCL has been divided into two subtypes, depending on whether the transcriptional profile of the tumor relates to an activated B cell or a germinal center B cell (ABC and GCB DLBCL, Alizadeh et al., 2000). More recent efforts classified DLBCL cases based on their genetic aberrations and identified several clusters with distinct mutational profiles (Chapuy et al., 2018, Schmitz et al., 2018, Wright et al., 2020). The MCD/C5 cluster is characterized by recurrent mutations in MYD88, PRDM1and frequent amplifications of BCL2, amongst others. We recently showed that mice harboring a B cell-specific Myd88 L252Pmutation (orthologous position of the human p.L265P mutation) develop B cell proliferation and occasional transformation into DLBCL (Knittel et al., 2016). Lymphomagenesis is further increased when Myd88 L252Pis combined with BCL2overexpression and a genetically engineered block in plasmacytic differentiation by loss of Prdm1or overexpression of Spib(Flümann et al., 2021).

Published
2023
Full Text
View/download PDF

41. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Author

Schuster, Stephen J, Fowler, Nathan, Dickinson, Michael, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie L., Chavez, Julio C, Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A, Ho, Phoebe Joy, Perez-Simon, Jose A., Chen, Andy, Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andrés José María, Teshima, Takanori, Patten, Piers, McGuirk, Joseph P, Petzer, Andreas L, Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Zia, Aiesha, Awasthi, Rakesh, Paule, Ines, Germano, Davide, Ramos, Roberto Javier, Hsu, Pei, Thieblemont, Catherine, and Dreyling, Martin

Abstract

Background: Tisagenlecleucel is approved in the United States and Europe for adults with relapsed/refractory follicular lymphoma (r/r FL) after ≥2 lines of prior therapy. The primary analysis of the Phase II ELARA trial (median follow-up: 17 months) reported high response rates and a favorable safety profile in heavily pretreated patients with r/r FL. Here we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after a median follow-up of more than 3 years.

Published
2023
Full Text
View/download PDF

42. Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Author

Ruckdeschel, Anna, Sabrina, Koemm, Topp, Max S., Greil, Richard, Melchardt, Thomas, Lenz, Georg, Kerkhoff, Andrea, Shumilov, Evgenii, Hess, Georg, Baumgaertner, Marta, Thurner, Lorenz, Age Kos, Igor, Mayer, Stephanie, Ayuk, Francis A., Krause, Rolf, Herling, Marco, Vucinic, Vladan, Chapuy, Claudia, Illerhaus, Gerald, Knott, Markus, Viardot, Andreas, Grunenberg, Alexander, Dietrich, Sascha, Caille, Leandra, Tometten, Mareike C., Cho, Hyunyee Rosa, Scholz, Julia, Mueller, Fabian, Prochazka, Katharina, Chapuy, Bjoern, Böckle, David, von Tresckow, Bastian, Schub, Natalie, Gelbrich, Götz, Einsele, Hermann, and Duell, Johannes

Abstract

Background

Published
2023
Full Text
View/download PDF

45. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Author

Moskowitz, Craig H., primary, Zinzani, Pier Luigi, additional, Fanale, Michelle A., additional, Armand, Philippe, additional, Johnson, Nathalie A., additional, Radford, John A., additional, Ribrag, Vincent, additional, Molin, Daniel, additional, Vassilakopoulos, Theodoros P., additional, Tomita, Akihiro, additional, von Tresckow, Bastian, additional, Shipp, Margaret A., additional, Gustafson, Eric, additional, Zhang, Yinghua, additional, Ricart, Alejandro Daniel, additional, Balakumaran, Arun, additional, and Chen, Robert W, additional

Published
2016
Full Text
View/download PDF

48. Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Author

Kreissl, Stefanie, primary, Goergen, Helen, additional, von Tresckow, Bastian, additional, Behringer, Karolin, additional, Markova, Jana, additional, Lohri, Andreas, additional, Meissner, Julia, additional, Zijlstra, Josée M, additional, Greil, Richard, additional, Topp, Max S., additional, Sökler, Martin, additional, Döhner, Hartmut, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2015
Full Text
View/download PDF

49. Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Goergen, Helen, additional, Pluetschow, Annette, additional, Behringer, Karolin, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul, additional, Fuchs, Michael, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results